CAJ | 학술논문

目的：分析氯吡格雷合并辛伐他汀对急性冠脉综合症患者(ACS)血脂和高敏C反应蛋白(hs-CRP)的影响。方法：选取经临床诊断为ACS的患者130例，其中54例接受常规辛伐他汀治疗，76例接受辛伐他汀联合氯吡格雷治疗，分析治疗40 d后患者hs-CRP及血脂的变化。结果：两组患者治疗40 d后血脂及hs-CRP均下降，但联合用药组hs-CRP下降明显，两组血脂下降无显著差异。结论：氯吡格雷联合辛伐他汀能显著降低ACS患者血浆中hs-CRP水平，有利于对炎症的控制和抑制斑块生长。
목적：분석록필격뢰합병신벌타정대급성관맥종합증환자(ACS)혈지화고민C반응단백(hs-CRP)적영향。방법：선취경림상진단위ACS적환자130례，기중54례접수상규신벌타정치료，76례접수신벌타정연합록필격뢰치료，분석치료40 d후환자hs-CRP급혈지적변화。결과：량조환자치료40 d후혈지급hs-CRP균하강，단연합용약조hs-CRP하강명현，량조혈지하강무현저차이。결론：록필격뢰연합신벌타정능현저강저ACS환자혈장중hs-CRP수평，유리우대염증적공제화억제반괴생장。
Objective: To analysis the effects of clopidogrel combined with simvastatin on blood lipids and high sensitivity C-reactive protein (hs-CRP) in patients with acute coronary syndrome (ACS). Methods: One hundred and thirty patients with ACS were divided into two groups:simvastatin group (54 patients) and simvastatin combined with clopidogrel group (76 patients). The levels of blood lipids and hs-CRP were detected before and 40 days after treatment. Results: The hs-CRP and blood lipids levels of patients significantly decreased in two groups. Compared with simvastatin group, the hs-CRP levels significantly decreased, but the blood lipids levels had not significant decreased. Conclusion: Treatment with clopidogrel combination with simvastatin can decrease the blood hs-CRP. It suggest that it may inhibit inflammatory responses, increase atherosclerotic plaque stabilization in ACS patients.